Galena Biopharma to Present at the BIO CEO & Investor Conference
February 02 2016 - 6:05AM
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company
committed to the development and commercialization of targeted
oncology therapeutics that address major unmet medical needs, today
announced that Mark W. Schwartz, Ph.D., President and Chief
Executive Officer will present a corporate update at the BIO CEO
& Investor Conference. The presentation will take place on
Monday, February 8, 2016 at 11:30 a.m. ET at the Waldorf Astoria
Hotel in New York, NY.
The presentation will be webcast and available on
the Investors section of the Company's website at
http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical
company committed to the development and commercialization of
targeted oncology therapeutics that address major unmet medical
needs. Galena’s development portfolio is focused primarily on
addressing the rapidly growing patient populations of cancer
survivors by harnessing the power of the immune system to prevent
cancer recurrence. The Company’s pipeline consists of multiple mid-
to late-stage clinical assets, including novel cancer immunotherapy
programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax
is currently in a pivotal, Phase 3 clinical trial with several
concurrent Phase 2 trials ongoing both as a single agent and in
combination with other therapies. GALE-301 is in a Phase 2a
clinical trial in ovarian and endometrial cancer and in a Phase 1b
given sequentially with GALE-302. For more information, visit
www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
ir@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2024 to May 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From May 2023 to May 2024